The undersigned organizations are writing, in anticipation of the reintroduction of the Elijah E.  Cummings Lower Drug Costs Now Act (i.e., H.R. 3), to urge Congress to keep any international reference pricing proposals (including “International Pricing Index” or “Most Favored Nation”)  out of drug pricing reform legislation. International reference pricing will have an outsized negative impact on people with Alzheimer’s disease and related dementias (ADRD), as well as decimate the clinical development of therapies for ADRD and other complex co-occurring medical conditions experienced by many people living with ADRD. Additionally, such reference pricing would undermine critical elements of the Affordable Care Act, the Rehabilitation Act,  the Americans with Disabilities Act, and the 2020 DNC Platform while exacerbating health disparities in direct contradiction of the Biden Administration’s core promise to advance health equity.

Read the Full Letter